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In this thesis, the use of positron emission tomography (PET) and its value in clinical
oncology are reviewed. Specific investigations in patients with soft tissue sarcoma,
breast cancer, bone tumors, testicular cancer, gastroesophageal tumors and
unknown primary tumors are discussed.
The INTRODUCTION describes some of the current problems in diagnosing
cancer. Histopathological diagnosis is based on a biopsy specimen that may not be
representative of the whole tumor. The extension of the tumor may not be assessed
accurately because of a low sensitivity of the imaging technique for a specific
indication. Also, the changed anatomy after preceding therapy can overstrain the
possibilities of conventional imaging techniques to detect a (recurrent) tumor. Once
treatment has been initiated, it can be difficult o assess its effects because the size
of a tumor is not strictly correlated with the amount of viable tumor cells. Up to now, a
surgical biopsy or resection of the tumor will ultimately determine the outcome of
therapy response. PET is at some points superior to conventional nuclear imaging
techniques, with its high resolution, the fact that it is not limited to anatomical
structures and its possibility to quantify metabolic processes. PET may therefore be
of use in overcoming some of these problems.
Positron emitting radionuclides are made in a device in which charged
particles can be accelerated to a speed at which they can cause nuclear reactions.
By focussing the beam of accelerated particles onto a target, a nuclear eaction with
the target takes place. With different targets, different end products can be obtained
and can be used in the synthesis of more complex radiopharmaceuticals that can be
administrated to patients. Applied radionuclides in PET are 11C, "N, "O and 18F.
These isotopes have a surplus of positive nuclear particles. Because this is an
unstable situation, these radionuclides either capture an electron or emit a positron
to achieve stability. The emitted positron slows down until it meets an electron on its
way. The two antiparticles annihilate and are transformed into two photons that emit
simultaneously under an angle of 180". When the two photons are detected in
opposite detectors of the PET camera, the line at which the annihilation has taken
place is known, and the distribution of annihilations (and therefore the distribution of
the radiopharmaceutical) can be reconstructed.
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Emission scanning can be performed statically, scanning one position for a fixed time
period or dynamically. A static image is very well suited for visual evaluation and
tumor/nontumor atio calculations. Several static emission scans from consecutive
levels form one "whole-body scan" when they are projected simultaneously on the
computer display. This technique is most suited for tumor detection and staging
purposes. During dynamic scanning several successive images are acquired. When
a metabolic model and mathematical techniques are applied, the metabolic rate of a
tumor can be calculated. With the tracer 18F-fluoro-2-deoxy-o-glucose (FDG), the
glucose utilization of tissues can be determined and with t--[1-11C]tyrosine (TYR), the
protein synthesizing activity of tumor tissue can be assessed.
CHepten 2 describes the utility of PET to analyze the tumor metabolism in
vivo. Glucose metabolism and protein synthesis are discussed more extensively. We
compared FDG and TYR as tumor tracers in patients with suspected breast cancer
and studied the correlation between metabolic values calculated from dynamic and
the easier to obtain static scans. All malignant tumors were visualized with both FDG
and TYR but the visual contrast was better with FDG. Uptake in fibrocystic disease
was more prominent with FDG than with TYR. No major differences between
different static calculation methods for metabolic values were found.
In a second study, the glucose metabolism in patients with various types of
bone lesions was investigated. All lesions but one were clearly visualized with FDG-
PET. The glucose metabolism was not higher for malignant han for benign lesions
and there was a large overlap between the MRglc of benign and malignant lesions.
FDG-PET appears therefore suitable to visualize bone tumors, but with the
quantification of the glucose metabolism, it is not possible to differentiate between
benign and malignant bone tumors. There does not seem to be a clear correlation
between the MRglc and the biologic aggressiveness of bone tumors.
Furthermore, we studied the relation of the metabolism as assessed with PET
and histopathological tumor parameters of soft tissue tumors before and after
therapy in patients who undenruent either FDG or TYR PET. The glucose
consumption correlated with the tumor grade and the mitotic rate, but not with
proliferation and necrosis. There was no longer a correlation with the mitotic rate
after therapy. The protein synthesis rate correlated with the tumor grade, the mitotic
rate and the proliferation. After therapy, correlation with mitosis and proliferation had
improved, and a negative correlation was found between PSR and necrosis. These
results validate the use of both FDG and TYR to give an in vivo indication of
histological tumor parameters. However, FDG gives a better indication of the tumor
grade, whereas TYR is more accurate in predicting the mitotic rate and proliferation,
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especially after therapy. FDG may therefore not be the most suited tracer for
monitoring therapy. TYR may be more appropriate for that purpose.
Finally, the potential of TYR to visualize a number of different umors outside
the central nervous system and to quantify their protein synthesis rates (PSRs) was
investigated. Sensitivity was 94o/o. PSR in tumor tissue was higher than in the
corresponding contralateral normal tissues. PSR in malignant tumors was higher
than in benign tumors and TYR appeared therefore to be a good tracer for the
imaging of malignancies.
Before anything can be said about tumor biology, the tumor must be identified
to obtain tissue for histologic examination. Also, reliable calculations regarding
metabolism can only be done on an identifiable tumor. Localization of tumors is
therefore the basis of all oncology PET-research. In CHAPTER 3 the value of PET
for detection of tumors is discussed. We studied the applicability of PET for detection
of primary tumors in patients with metastases of various tumor types of unknown
origin after unsuccessful conventional diagnostic work-up. With FDG-PET, all known
metastatic tumor sites but one were visualized and additional metastases were
discovered in 17%. The primary tumor was identified in an additional24o/o. Despite a
negative PET study, the primary lesion was identified in a later phase in another
14%. Survival was not altered by finding the primary tumor. The clinical relevance of
PET information in this setting is therefore limited.
It is often difficult to detect a local recurrence of soft tissue sarcomas due to
disturbance of the normal anatomy by previous surgery and radiotherapy. PET is not
hampered by changed anatomy, because metabolism is reflected, not structure. PET
has therefore the ability to differentiate between viable tumor tissue and fibrosis or
necrosis. We studied the use of FDG-PET for the detection of a local recurrence in
patients with proven or suspected local recurrence of a soft tissue sarcoma.
Sensitivity was 93%. A correlation was found between the histological malignancy
grade and the metabolic rate of glucose consumption. PET with FDG is therefore a
useful addition to the diagnostic armamentarium for detecting local recurrence of soft
tissue sarcomas.
Cnnpfen 4 describes the utility of PET for staging of cancer. With PET, the
whole-body can be studied in one session, examining lymph nodes, bone, lung and
liver all at once. For some indications the conventional staging techniques are very
insensitive or burdensome. We studied the accuracy of FDG-PET in staging and
estimating resectability of oesophageal or gastroesophageal junction tumors and
compared the findings to computed tomography and surgical findings. The primary
tumor was visualized in 81o/o f patients with CT and in 96% with PET. Neither CT
nor PET was suited to assess the extent of wall invasion. Surgically assessed nodal
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status corresponded in 620/o with CT and in 90% with PET. The diagnostic accuracy
of cr in determining resectability was 65% and for pET 8g%. For cr and pET
together, this was 92%. FDG-PET can therefore be of importance for staging
patients with oesophageal tumors. PET and CT together would have decreased ill-
advised surgery with 90%.
CHRpfen 5 describes the ability of PET to monitor anti-cancer treatment. The
metabolism of the tumor as measured with PET may be a reliable indicator of the
amount of viable tumor cells between fibrosis and necrosis after therapy. PET may
be applied during therapy to predict early in the treatment course the response to
therapy and therefore the necessity to continue treatment.
We studied the utility of FDG-PET to evaluate the outcome of chemotherapy in
patients with malignant bone tumors. After three or four courses of chemotherapy,
the glucose metabolism of the tumor in patients that responded well decreased
markedly whereas the glucose metabolism of the tumor in poor responders did not.
In a second study we investigated whether ryR-PET can predict the outcome
of neoadjuvant chemotherapy in an early phase in patients with locally advanced
breast cancer. TYR uptake decreased clearly in the patients who would eventually
have a complete histological response. There was a small decrease in case of a
partial response and no change in case of stable disease. These preliminary results
suggest hat there is a role for PET with TYR in the early evaluation of breast cancer
therapy.
We also studied the utility of WR-PET for the detection and evaluation of
therapy of metastatic non-seminoma germ cell tumors in order to reduce the number
of operations in patients with a residual retroperitoneal tumor mass after therapy.
However, before therapy PET showed increased focal uptake of TyR in the
retroperitoneum of only 20o/o of these patients. Because of these disappointing
results, no post-treatment scans were performed. WR-PET is therefore not suited to
visualize the apparently slowly proliferating metastatic non-seminoma gem cell
tumors nor to determine the nature of a residual retroperitoneal mass after
chemotherapy.
Finally, we explored the use of Hrlso-pET for the prediction of sensitivity of
tumors to therapy, and the evaluation of response to treatment. All tumors were
clearly visualized with PET. lt could be predicted from the Hr15O tumor activity before
therapy how a patient would respond to the subsequent reatment. Hrlso tumor
activity after therapy reflected the response to that therapy. H2150 pET may therefore
be used to both predict and evaluate the response to anti-cancer treatment.
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PET has proven its value for clinical oncology. Many implementations are feasible
with a technique that visualizes the tumor metabolism and creates possibilities for in
vivo tumor analysis, detection, staging and monitoring therapy. Besides the clinical
applications, PET will enlarge our knowledge of metabolic tumor processes.
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